IMMUNOLOGICAL CHANGES IN THE TREATMENT OF ANTIPHOSPHOLIPID SYNDROME IN PREGNANT WOMEN

Abstract

Relevance: One of the leading factors that reduce the level of reproductive health is antiphospholipid syndrome. Aim: Determination of immunological changes during the treatment of APS in pregnant women. Materials and methods: The study was conducted among pregnant women with APS, which were divided into 2 groups. The groups were representative in terms of age, parity, obstetric and somatic pathology, but differed in treatment methods. The first comparison group (traditional management) included 28 pregnant women with APS. In this group, all pregnant women received traditional therapy for APS, including anticoagulants, antiplatelet agents, and glucocorticoids. The second - main group included 48 pregnant women with APS. In this group, all pregnant women, along with traditional therapy, additionally received systemic enzyme therapy and plasmapheresis. Results: Significant differences were also recorded between the control and main groups in the level of circulating immune complexes 10 and 30 days after the start of treatment, which amounted to 23.6% and 29.7%, respectively (p<0.05; p<0.01). In the main group, positive dynamics were noted after 10 days, a decrease in the absolute and relative number of pregnant women with a diagnostic titer of both markers of VA and aCL (by 41.7%). Relative indicators of detection of the diagnostic titer of VA and aCL after 30 days tended to decrease compared to the control, the differences with the traditional management group remained reliable (p<0.05). According to the results of the study, the content of immunoglobulins in pregnant women in the control group and the main group did not have significant differences. Conclusion: Thus, complex therapy of antiphospholipid syndrome is reliably effective and leads to faster normalization of immune system parameters in pregnant women with APS.